Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.

British journal of clinical pharmacology - 1 Jan 2005

Zhang Yifan, Zhong Dafang, Si Dayong, Guo Yingjie, Chen Xiaoyan, Zhou Hui

Abstract excerpt

AIMS: To investigate the pharmacokinetics of lornoxicam and the relationship with CYP2C9 polymorphism in healthy Chinese subjects. METHODS: A single oral dose of 8 mg lornoxicam was administered to 18 healthy Chinese male subjects. Plasma was sampled for 24 h post dose, and plasma concentrations of lornoxicam were measured using a validated LC/MS/MS method. CYP2C9 genotype was determined by polymerase chain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Genotype

Share to Heterozygote

Share to Homozygote

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 15606435
DOI: 10.1111/j.1365-2125.2005.02223.x
PMCID: PMC1884973

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.PMID 15606435Read ↗

Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.Semantic proximity Read ↗

Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.Semantic proximity Read ↗

[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].Semantic proximity Read ↗

Effect of the CYP2C9*3 allele on lornoxicam metabolism.Semantic proximity Read ↗

Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.Semantic proximity Read ↗

Identification of a novel variant CYP2C9 allele in Chinese.Semantic proximity Read ↗

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.Semantic proximity Read ↗

Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide.Semantic proximity Read ↗

Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Semantic proximity Read ↗

Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic (PBPK) Modeling of Lornoxicam: Exploration of doses for CYP2C9 Genotypes and Patients with Cirrhosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.